Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 3Completed 3Withdrawn 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Head & Neck 2Thoracic 1Genitourinary 1CNS 1

Conditions

Mycosis Fungoides 1Hodgkin Disease 1

Interventions

Rituximab 55Cyclophosphamide 45Vincristine 23fludarabine phosphate 21Cytarabine 20fludarabine 19Etoposide 19Prednisone 18Bendamustine Hydrochloride 18ibrutinib 17Methotrexate 17Doxorubicin 17Lenalidomide 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 12venetoclax 11Melphalan 11Dexamethasone 11Whole-Body Irradiation 8Tacrolimus 8Busulfan 8Brentuximab Vedotin 8Biopsy 8pembrolizumab 7duvelisib 7Nivolumab 7Mycophenolic Acid 7Gemcitabine 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × cemiplimab × Lymphoid × Clear all
NCT05538988 2025-06-27

BIOSELECT

AHS Cancer Control Alberta

Phase 1/2 Withdrawn
Lymphoid

Mycosis Fungoides

NCT04373083 2021-01-15

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Regeneron Pharmaceuticals

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡